OBJECTIVE: The hepatotoxic action of arsenic, when used as a therapeutic agent, has long been recognized. Data on liver involvement following chronic exposure to arsenic-contaminated water are scanty. We report the nature and degree of liver involvement on the basis of hospital-based and cohort follow-up studies in patients who consumed arsenic-contaminated drinking water for 1 to 15 years. METHODS: 248 patients with evidence of chronic arsenic toxicity underwent clinical and laboratory examinations including liver function tests and HBsAg status. Liver biopsy was done in 69 cases; in 29 patients, liver arsenic content was estimated by neutron activation analysis. A cohort follow up of 23 patients who took arsenic-free water for 2-12 years was also carried out. RESULTS: Hepatomegaly was present in 190 of 248 patients (76.6%). Noncirrhotic portal fibrosis (91.3%) was the predominant lesion in liver histology. The maximum arsenic content in liver was 6 mg/Kg (mean 1.46 [0.42], control value 0.16 [0.04]; p < 0.001); it was undetected in 6 of 29 samples studied. Cohort follow-up studies showed elevation of globulin in four cases and development of esophageal varices in one case. CONCLUSION: We report the largest number of patients with liver disease due to chronic arsenicosis from drinking arsenic-contaminated water. Noncirrhotic portal fibrosis is the predominant lesion in this population.
OBJECTIVE: The hepatotoxic action of arsenic, when used as a therapeutic agent, has long been recognized. Data on liver involvement following chronic exposure to arsenic-contaminated water are scanty. We report the nature and degree of liver involvement on the basis of hospital-based and cohort follow-up studies in patients who consumed arsenic-contaminated drinking water for 1 to 15 years. METHODS: 248 patients with evidence of chronic arsenic toxicity underwent clinical and laboratory examinations including liver function tests and HBsAg status. Liver biopsy was done in 69 cases; in 29 patients, liver arsenic content was estimated by neutron activation analysis. A cohort follow up of 23 patients who took arsenic-free water for 2-12 years was also carried out. RESULTS:Hepatomegaly was present in 190 of 248 patients (76.6%). Noncirrhotic portal fibrosis (91.3%) was the predominant lesion in liver histology. The maximum arsenic content in liver was 6 mg/Kg (mean 1.46 [0.42], control value 0.16 [0.04]; p < 0.001); it was undetected in 6 of 29 samples studied. Cohort follow-up studies showed elevation of globulin in four cases and development of esophageal varices in one case. CONCLUSION: We report the largest number of patients with liver disease due to chronic arsenicosis from drinking arsenic-contaminated water. Noncirrhotic portal fibrosis is the predominant lesion in this population.
Authors: Min Tan; Robin H Schmidt; Juliane I Beier; Walter H Watson; Hai Zhong; J Christopher States; Gavin E Arteel Journal: Toxicol Appl Pharmacol Date: 2011-09-29 Impact factor: 4.219
Authors: Veronica L Massey; Kendall S Stocke; Robin H Schmidt; Min Tan; Nadim Ajami; Rachel E Neal; Joseph F Petrosino; Shirish Barve; Gavin E Arteel Journal: Toxicol Appl Pharmacol Date: 2015-03-08 Impact factor: 4.219
Authors: Ali Sharif; Muhammad Ashraf; Aqeel Javeed; Aftab Ahmed Anjum; Muhammad Furqan Akhtar; Bushra Akhtar; Ammara Saleem Journal: Environ Sci Pollut Res Int Date: 2016-09-19 Impact factor: 4.223
Authors: Maria Grau-Perez; Ana Navas-Acien; Inmaculada Galan-Chilet; Laisa S Briongos-Figuero; David Morchon-Simon; Jose D Bermudez; Ciprian M Crainiceanu; Griselda de Marco; Pilar Rentero-Garrido; Tamara Garcia-Barrera; Jose L Gomez-Ariza; Jose A Casasnovas; Juan C Martin-Escudero; Josep Redon; F Javier Chaves; Maria Tellez-Plaza Journal: Environ Pollut Date: 2018-02-21 Impact factor: 8.071